Biocon leadership reshuffle: CEO, CFO changes in 2026

Leadership changes tied to Biocon Biologics integration

Biocon Limited has announced a set of leadership changes that take effect from April 1, 2026, aligning with its planned integration of Biocon Biologics Limited (BBL). The decisions were approved by the Board of Directors at its meeting held on Friday, March 27, 2026. The changes include the exit of the company’s Managing Director and Chief Executive Officer and a change in the finance leadership. Biocon’s disclosures indicate the moves are part of an organisational reset as the group combines operations and leadership responsibilities across Biocon and Biocon Biologics. The company is listed on BSE (532523) and NSE (BIOCON). The key transitions are also linked to shareholder approvals sought through a postal ballot process.

Board meeting on March 27 sets April 1 as effective date

Biocon said the Board approved “crucial leadership changes” to be implemented from April 1, 2026. The board decisions were taken following recommendations from the Nomination and Remuneration Committee for key appointments. Biocon also described these changes as being “in line with the planned integration” of Biocon Biologics. The company specified that some resignations would be effective from the close of business hours on March 31, 2026, creating a clean cutover into the new structure starting April 1. The announcements cover appointments at the CEO, CFO, and key managerial personnel levels, along with changes in senior management.

Siddharth Mittal resigns as MD and CEO from March 31, 2026

The Board accepted the resignation of Mr. Siddharth Mittal (DIN: 03230757) as Chief Executive Officer and Managing Director. The resignation is effective at the close of business hours on March 31, 2026. Biocon stated that Mittal is set to “assume another leadership role within the Biocon Group,” indicating a transition rather than a departure from the wider group. The timing places the leadership change immediately ahead of the April 1, 2026 effective date for the broader restructuring.

Mukesh Kamath steps down as Interim CFO

Biocon also announced the resignation of Mr. Mukesh Kamath as Interim Chief Financial Officer, effective March 31, 2026. The board’s acceptance of the resignation was disclosed as part of the same package of leadership decisions. The company indicated that Kamath will transition to a new role within the Group. With the CFO function directly linked to integration execution, funding, and compliance, this change is positioned as part of the shift to a new leadership setup beginning April 1, 2026.

Shreehas Tambe appointed CEO and MD for five years, subject to approval

Mr. Shreehas Pradeep Tambe (DIN: 09796480), who was CEO and Managing Director of Biocon Biologics, has been appointed as an Additional Director effective April 1, 2026. Biocon said he will subsequently take on the roles of Chief Executive Officer and Managing Director (KMP) for five years from April 1, 2026, subject to shareholder approval. The company also disclosed that the appointment follows approvals from the Nomination and Remuneration Committee and the Board. The proposed term is explicitly stated as five (5) years.

Kedar Narayan Upadhye appointed CFO; other KMP and senior roles updated

Alongside the CEO transition, Biocon appointed Mr. Kedar Narayan Upadhye as Chief Financial Officer. The board also designated Mr. Akhilesh Nand as Key Managerial Personnel. In senior management, Biocon named Mr. Naveen Narayanan and Mr. Mandar Shrikant Ghatnekar as Senior Management Personnel. Separately, the board approved the cessation of seven Senior Management Personnel with effect from March 31, 2026. Biocon did not provide names of the seven individuals in the provided text, but the cessation date aligns with the leadership cutover.

Postal ballot seeks shareholder approvals, results due by June 9, 2026

Biocon’s postal ballot notice dated May 7, 2026 seeks member approval for multiple items, including the appointment of Shreehas Tambe as CEO and Managing Director. The company stated that the scrutinizer will submit the report after completing vote scrutiny. Results of the postal ballot are to be declared on or before Tuesday, June 9, 2026. Biocon also said that if resolutions are passed by the requisite majority, the date of passing will be deemed to be Sunday, June 7, 2026, being the last date specified for remote e-voting. The company indicated results will be shared with NSE and BSE and uploaded to its website and KFintech’s e-voting platform.

Preferential issues linked to Biocon Biologics acquisition and later changes

Biocon referenced an earlier intimation dated December 6, 2025, where the Board approved the acquisition of equity shares of Biocon Biologics Limited and the issuance and allotment of Biocon equity shares on a preferential basis under SEBI ICDR Regulations, 2018. It also disclosed that on December 31, 2025, 171,279,553 equity shares of face value Rs 5 each were issued and allotted on a preferential basis at an issue price of Rs 405.78 per share, as consideration for the acquisition described in the filing.

Separately, in the 2026 postal ballot context, Biocon included a proposal to issue equity shares on a preferential basis for consideration other than cash. The text also references a proposed issue “up to 8,792,317 equity shares” at Rs 376.16 per share, and another communication noting a revised proposal with a minor change in floor price and issue terms. In that revised set, the number of equity shares proposed is stated as 8,786,362 at an issue price of Rs 376.41 per share, and a swap ratio of 0.76159, described as 76.159 Biocon shares for every 100 Biocon Biologics shares.

Key facts snapshot

Capital and remuneration items included in shareholder agenda

The postal ballot includes a proposal to revise the remuneration of Ms. Kiran Mazumdar-Shaw, Executive Director (designated as Executive Chairperson). The notice states that, effective from April 1, 2026 during her remaining tenure as Executive Chairperson, the aggregate remuneration payable by the company shall not exceed Rs 21 crore per annum, excluding certain components as referenced in the notice.

A separate summary table in the provided text also describes a proposal to approve preferential allotment of approximately 8.8 million equity shares at Rs 376.16 per share aggregating approximately Rs 330 crore for consideration other than cash. The same set of materials lists the CEO and MD appointment as a special resolution for a five-year term starting April 1, 2026, and includes multiple board appointment items effective from August 1, 2026 for different director categories.

Market impact: what changes, and what remains procedural

From a market and investor perspective, the immediate change is executive accountability, with the Biocon Biologics CEO set to lead Biocon as CEO and MD from April 1, 2026. The CFO appointment also matters because the integration process and any share issuance actions typically require strong financial oversight and timely disclosures. However, multiple elements remain subject to shareholder approval, including the CEO and MD appointment as described in the postal ballot notice.

The capital-structure items referenced in the text, including preferential issuance for non-cash consideration and share-swap related mechanics, indicate that the integration is being executed through a combination of governance actions and equity issuance. Investors will also track the formal outcome of the postal ballot, with the company specifying June 9, 2026 as the outer date for result declaration.

Why this matters: governance continuity during integration

Biocon has presented the leadership transition as part of an integration plan, rather than a stand-alone change. Moving the Biocon Biologics CEO to the top role at Biocon suggests an effort to align strategic direction between the parent and the biologics subsidiary. At the same time, the resignation of both the MD and CEO and the interim CFO on the same effective date points to a coordinated handover.

The timeline also matters because the governance process extends beyond the boardroom. Shareholder approval through postal ballot is explicitly required for key resolutions, including senior appointment approvals and other items like remuneration revisions and preferential issuance proposals. The company has set out dates for e-voting and the declaration of results, giving investors clear milestones to monitor.

Conclusion

Biocon’s board-approved leadership changes, effective April 1, 2026, mark a formal transition linked to its planned integration of Biocon Biologics. The CEO and CFO changes take effect immediately after the March 31, 2026 close of business, while several related resolutions await shareholder approval through a postal ballot. The next confirmed milestone is the postal ballot result, which Biocon said will be declared on or before June 9, 2026, with June 7, 2026 treated as the deemed date of passing if approved by the requisite majority.